

**Supplementary Table S1.** Comparison of the methylation values of CIMP markers and MLH1 IHC results between 8 *MLH1*-methylated non-dysplastic SSA/Ps (case ID, SSA-xx; included in the study samples) and 2 *MLH1*-methylated dysplastic SSA/Ps (case ID, SSA-D-xx; not included in the study samples)

Case ID	Age (yr)	PMR value of CIMP marker								MLH1 IHC	Morphologic dysplasia
		CACNA1G	CRABP1	IGF2	MLH1	NEUROG1	p16	RUNX3	SOCS1		
SSA-04	78	46.6	57.4	38.9	10	59.2	64.7	73.6	41.1	No loss	Absent
SSA-10	50	25.6	20.3	26.1	5.8	32.1	16.8	0	0	No loss	Absent
SSA-23	60	1.2	12.1	4.3	9	8.7	0	0	0	No loss	Absent
SSA-38	56	0	37.2	27.2	5.9	23.2	0	16.4	0	No loss	Absent
SSA-55	71	15.2	10.1	4	5	16.3	9.8	5.3	7.7	No loss	Absent
SSA-66	63	10.6	27.4	0	26.3	40.4	25.5	0	13.7	Partial loss	Absent
SSA-92	74	46.2	51.4	38.7	12.9	39.1	66.5	13.4	0	No loss	Absent
SSA-107	53	74.3	86.1	0.9	8.9	78.3	57	18.5	0	No loss	Absent
SSA-D-01	65	48.71	41.24	12.71	36.04	18.13	29.26	12.64	22.96	Complete loss	Present
SSA-D-04	55	15.1	13.21	17.41	57.07	51.05	10.63	21.02	0	Complete loss	Present

CIMP, CpG island methylator phenotype; IHC, immunohistochemistry; SSA/Ps, sessile serrated adenomas/polyps; PMR, percentage of methylated reference.